

MOL #36772

Identification of two New Synthetic Histone Deacetylase Inhibitors that Modulate Globin Gene Expression in Erythroid Cells from Normal Donors and Thalassemic Patients

Antonello Mai, Katija Jelacic, Dante Rotili, Antonella Di Noia, Elena Alfani, Sergio Valente, Lucia Altucci, Angela Nebbioso, Silvio Massa, Renzo Galanello, Gerald Brosch, Anna Rita Migliaccio, and Giovanni Migliaccio

Istituto Pasteur - Fondazione Cenci Bolognetti, Dipartimento di Studi Farmaceutici, Università degli Studi di Roma "La Sapienza", P.le A. Moro 5, 00185 Roma, Italy (A.M., D.R., S.V.); Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, viale Regina Elena 299, 00161 Roma, Italy (K.J., A.D.N., E.A., G.M.); Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, via A. Moro, 53100 Siena, Italy (S.M.); Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, vico L. De Crescchio 7, 80138 Napoli, Italy (L.A., A.N.); Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Cagliari, Cagliari, Italy (R.G.); Division of Molecular Biology, Biocenter, Innsbruck Medical University, Fritz-Preglstrasse 3, 6020 Innsbruck, Austria (G.B.); Dipartimento di Ematologia, Oncologia e Medicina Molecolare, Istituto Superiore di Sanità, viale Regina Elena 299, 00161 Roma, Italy, and Department of Medicine and MPD-RC, University of Illinois at Chicago, Chicago, USA (A.R.M.)

MOL #36772

Running title page

Running title: HDACi and HbF reactivation.

Address correspondence to:

Anna Rita Migliaccio

Dipartimento di Ematologia, Oncologia e Medicina Molecolare, Istituto Superiore di Sanità, viale Regina Elena 299, 00161 Roma, Italy, and Department of Medicine and MPD-RC, University of Illinois at Chicago, Chicago, USA

Tel.: 003906-4990-2690;

Fax: 003906-4938-7143;

e-mail: migliar@iss.it

Number of text pages: 23

Number of tables: 2

Number of figures: 9

Number of references: 45

Number of words in the *Abstract*: 248

Number of words in the *Introduction*: 749

Number of words in the *Discussion*: 1419

ABBREVIATIONS: HbF, fetal hemoglobin; HDAC, histone deacetylase; HDACi, histone deacetylase inhibitors; AHSP, alpha hemoglobin stabilizing protein; HPFH, hereditary persistence of fetal hemoglobin; AraC, cytosine arabinoside; HAT, histone acetyltransferase; TSA, trichostatin A; SAHA, suberoylanilide hydroxamic acid; DMSO, dimethyl sulfoxide; HBSS, Hank's balanced salt solution; AFU, arbitrary fluorescence units; IMDM, Iscove's modified Dulbecco's medium; FBS, fetal bovine serum; EPO, erythropoietin; APHAs, aroyl pyrrolyl hydroxyamides; UBHAs, uracil-based hydroxyamides; HEMA, human erythroblast massive amplification; CCL, chronic lymphocytic leukemic.

MOL #36772

Abstract

We have identified two new histone deacetylase (HDAC) inhibitors (9 and 24) capable to induce the expression of γ -globin and/or β -globin promoter-driven reporter genes in a synthetic model of Hb switch. Both compounds also increased, with different mechanisms, the $\gamma/(\gamma+\beta)$ ratio expressed in vitro by normal human erythroblasts. Compound 9, increased the levels of γ -globin mRNA, and the $\gamma/(\gamma+\beta)$ ratio (both by 2-fold). Compound 24, increased by 3-fold the level of γ -globin and decreased by 2-fold that of β -globin mRNA, increasing the $\gamma/(\gamma+\beta)$ ratio by 6-fold, and raising (by 50%) the cell HbF content. Both compounds raised the acetylation state of histone H4 in primary cells, an indication that their activity was mediated through HDAC inhibition. Compound 9 and 24 were also tested as $\gamma/(\gamma+\beta)$ mRNA inducers in erythroblasts obtained from β^0 -thalassemic patients. Progenitor cells from β^0 -thalassemic patients generated in vitro morphologically normal pro-erythroblasts that, unlike normal cells, failed to mature in the presence of EPO and expressed low β -globin levels, but levels of the alpha hemoglobin stabilizing protein (AHSP) mRNA 10-times higher than normal. Both compounds ameliorated the impaired in vitro maturation in β^0 -thalassemic erythroblasts decreasing AHSP expression down to normal levels. In the case of two patients (out of 5 analyzed), the improved erythroblast maturation was associated with detectable increases in the $\gamma/(\gamma+\beta)$ mRNA ratio. The low toxicity exerted by compounds 9 and 24 in all of the assays investigated suggests that these new HDAC inhibitors should be considered for personalized therapy of selected β^0 -thalassemic patients.

Introduction

In mammals, the development of erythroid cells is characterized by sequential ontogenetic hemoglobin (Hb) switches. In man, the first embryonic to fetal Hb (HbF) switch occurs after two months of gestation and is followed by a switch from HbF to adult Hb (HbA), that begins at mid-gestation and is completed six months after birth. HbF expression is retained by a minority (1-3%) of normal adult red cells (Stamatoyannopoulos and Grosveld, 2001).

β -Thalassemia and sickle cell anemia are inherited genetic disorders, both arising from mutations in one of the genes, β -globin, encoding HbA. Sickle cell anemia is due to a miss sense mutation leading to glutamate - valine substitution at position 6 of the β -globin chain. β -Thalassemia may be traced to numerous genetic mutations resulting either in loss (more precisely defined β^0 -) or reduced β -globin expression (Olivieri, 1999). Both β -thalassemic and sickle cell patients are normal until birth, when their red cells contain HbF. Furthermore, sickle cell and β -thalassemia patients that co-inherit genetic mutations allowing to retain HbF production postnatally (Hereditary Persistence of Fetal Hemoglobin, HPFH, syndrome), have no or mild clinical phenotype (Olivieri, 1999). These observations, and additional clinical studies, have allowed to calculate that pharmacological re-activation of γ -globin production, up to ~10–20% of β -globin levels, in adult red cells would be sufficient to ameliorate the symptoms of sickle cell disease and β -thalassemia (Noguchi, 1988).

Numerous studies have been undertaken to identify HbF inducers for the cure of hemoglobinopathies. In primates, HbF has been induced by cell cycle-specific cytotoxic drugs [cytosine arabinoside (AraC) (Papayannopoulou et al., 1984) and hydroxyurea (Letvin et al., 1984)]. Both drugs also induced HbF in phase I-II clinical trials in patients with sickle cell disease and β -thalassemia (Platt et al., 1984; Veith et al., 1985), that have indicated hydroxyurea as the treatment of choice for sickle cell anemia (Bradai et al., 2003). This drug, however, is not devoid of counter indications, is not effective in all the sickle cell patients and has modest effects in the β -

MOL #36772

thalassemic patients. The search for additional and less toxic agents, therefore, continues (Atweh and Schechter, 2001).

Two enzyme superfamilies, Histone Acetyltransferases (HATs) and Histone Deacetylases (HDACs), exert antagonistic epigenetic controls on gene expression through chromatin remodelling (Hassig and Schreiber, 1997). HATs induce histone acetylation, favouring chromatin relaxation and exposing gene regulatory regions to the transcription machinery. HDAC catalyze histone deacetylation, resulting in the formation of tightly supercoiled, transcriptionally silent, “heterochromatin” regions (Felsenfeld and Groundine, 2003). Specific histone acetylation patterns have recently been shown to play a role in the murine β -globin switch, suggesting that HDACs might participate in the silencing complex that represses γ -globin expression (Forsberg et al., 2000). Hence, the hypothesis that HDAC inhibitors (HDACi) might represent pharmacological reactivators of HbF (Cao, 2004 a).

The proof-of-concept for the use of HDACi as pharmacologic HbF inducers was provided by the observation that sheep fetuses continuously infused with sodium butyrate, a well known although weak (millimolar range) HDACi, displayed delayed HbF to HbA switch (Perrine et al., 1988). Subsequent studies showed that butyrate, its analogues phenylbutyrate, valproic acid, additional short chain fatty acids, and their hydroxyamide derivatives, induce HbF synthesis in human erythroid cultures (Perrine et al., 1989), in adult baboons (Constantoulakis et al., 1989), in some β -thalassemia patients (Perrine et al., 1993; Sher et al., 1995), and in the majority of sickle cell patients (Atweh et al., 1999). The rapid metabolism, inconvenient mode of application, and weak HbF-inducing activity of these compounds, however, prompt the search for alternative HbF-inducing HDACi. A variety of HDACi, mostly with unrelated chemical structures [trichostatin A (TSA), trapoxin, suberoylanilide hydroxamic acid (SAHA), MS-275, apicidin, scriptaid and analogues], have been shown capable to induce HbF in vitro and/or in vivo (Cao et al., 2004 a; b). Their potential use for the cure of hemoglobinopathies remains unclear, due to their modest effects as HbF inducers and high cell toxicity.

MOL #36772

The aim of this study was to identify new, possibly less toxic, HDACi capable to induce HbF, using a two step screening strategy. First, HDACi were screened for their potential to increase expression of a γ -driven reporter in GM979 cells stably transfected with a dual luciferase reporter construct (Skarpidi et al., 2000). Second, selective compounds were evaluated for their capability to increase the $\gamma/(\gamma+\beta)$ ratio expressed in vitro by normal adult erythroblasts (Migliaccio et al., 2002). The two most potent compounds identified with this second screening, were finally tested for their ability to restore the impaired maturation of erythroblasts obtained in vitro from β^0 -thalassemic patients.

Material and Methods

Construction of the HDACi library. The synthetic schemes, experimental preparation procedures, physical and chemical data and registry number for the new compounds 2, 3, 13-19, and 23-25 are reported in supplemental data. Compounds 1, 4-12, and 20-22 were synthesized as previously described (see references in supplemental data). SAHA (Vorinostat) was purchased from Sigma Aldrich Chemical Co. (St. Louis, MO). The HDACi belong to the chemical classes of aroyl pyrrolyl hydroxyamides (APHAs, 1-6), aryloxopropenylpyrrolyl hydroxyamides (7-19), and uracil-based hydroxyamides (UBHAs, 20-25), and were tested against the maize deacetylases HD2, HD1-B (class I HDAC) and HD1-A (class II HDAC). Inhibitory assays were performed according to established procedures (Brosch et al., 1996a; Kolle et al., 1998) based on the ability of a compound to inhibit the maximal amount of tritiated acetic acid, quantified by scintillation counting, liberated from radioactively labeled chicken core histones by each purified enzyme. Briefly, maize HDACs (50 μ L) were first pre-incubated with increasing concentrations of compounds for 15 min on ice and then incubated for 30 min at 30 °C with total [3 H]acetate-prelabeled chicken reticulocyte histones (10 μ L of a 2 mg/mL solution). The reaction was stopped by adding 36 μ L of 1 M HCl/0.4 M acetate and 800 μ L of ethyl acetate. After centrifugation (10 000 g, 5 min), the radioactivity present in the supernatant (600 μ L) was counted in a Beckam Counter LS6500 scintillation counter. SAHA was included in the assay as reference, and blank solvents were used as negative controls. Maize HDACs were purified as described (Brosch et al., 1996b; Kolle et al., 1998). IC₅₀ values were calculated with the Excel software, and expressed as mean (\pm SD) of triplicate determinations as summarized in Supplemental Table 3. All of the compounds inhibited maize HDACs, although with a wide range of efficiency (IC₅₀ between 0.004 and 39 μ M). Four of them (8, 9, 11 and 12), were selectively active on class II enzymes (selectivity ratio > 10). None of them was selective for the class I enzyme. As expected on the basis of previous results (see references in supplemental data), the six compounds of the UBHA family expressed an IC₅₀ lower than SAHA. In particular, compound 24 was 2-30-fold more potent than SAHA in inhibiting the maize HD1-B and HD1-A.

MOL #36772

Activation of γ -driven Reporter Expression. The μ LCR β prRluc γ prFlucGM979 cell line was obtained by stably transfecting the murine erythroleukemia GM979 cell line with a dual luciferase reporter containing a 3.1-kb μ LCR cassette including the DNase I hypersensitive core of the 5' hypersensitive sites HS1, HS2, HS3, and HS4, linked to 315-bp of the human β -globin promoter and 1.4-kb of the γ -globin promoter driving the Renilla (R) and the Firefly (F) Luciferase gene, respectively (Skarpidi et al., 2000). μ LCR β prRluc γ prFlucGM979 cells, indicated from now on as GM979 for brevity, were maintained in RPMI 1640 containing 10% (vol/vol) FCS, 100 units/mL penicillin, 100 mg/mL streptomycin, 2 mM glutamine and 400 μ g/mL of G418 as described (Migliaccio et al., 2005). The effect of HDACi on the expression of the γ -driven reporter was evaluated by incubating the cells with increasing concentrations of each compound solubilized in DMSO (final concentration 0.1% v/v). Negative controls were represented by cells incubated with DMSO alone. After 4 days of incubation, cells were harvested and γ -Firefly (γ -F) and β -Renilla (β -R) luciferase activities determined in triplicate using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA), as described by the manufacturer. Luminescence was measured with the Lumat LB9507 Luminometer (EG&G Berthold, Wellesley, MA, USA) and expressed in Arbitrary Fluorescence Units (AFU). Results are expressed as mean (\pm SD) of triplicate assays and are presented both as absolute values and as activity ratios (γ -F AFU/ γ -F AFU + 2 β -R AFU).

Human Subjects. Buffy coats from the peripheral blood of at least 15-20 different normal donors were obtained from the Italian Red Cross Blood Bank, Rome, Italy. Blood from 5 β^0 -thalassemic patients was collected before routine transfusion at the Center for Studies on Thalassemia, University of Cagliari, Italy. All the patients were homozygous for the non-sense β^0 39 mutation (Trecartin et al., 1981). This mutation reduces β -globin mRNA expression through a non-sense mediated mRNA decay mechanism (Zhang et al., 1998), and should have no consequence on the conformation of the β -globin locus. Human blood was collected according to guidelines established by the local ethical committee for human subject studies.

MOL #36772

Cell Processing. Mononuclear blood cells were separated by centrifugation at 400g x 30' over Ficoll-Hypaque (Amersham-Pharmacia Biotec, Uppsala, Sweden). Light density cells were collected, washed with Hank's balanced salt solution (HBSS) supplemented with 1% (wg/vol) bovine serum albumin and either cultured directly or cryopreserved in 10% dimethyl-sulphoxide (Sigma, St Louis, Mo, USA).

Activation of the endogenous γ -globin gene in primary human erythroblasts. Human pro-erythroblasts were obtained by culturing light density blood cells (10^6 cells/mL) in Iscove's modified Dulbecco's medium (IMDM, Mascia Brunelli, Milan, Italy) containing fetal bovine serum (FBS, 20% v/v Hyclone, Logan, UT, USA), Stem Cell Factor (SCF, 10 ng/mL) (Amgen, Thousand Oaks, CA), erythropoietin (EPO, 1 u/mL) (Epoetina alfa, Dompè Biotech, Milan, Italy), Interleukin-3 (IL-3, 1 ng/mL) (Bouty, Milan, Italy), dexamethasone (10^{-6} M) (Sigma) and estradiol (10^{-6} M) (Sigma), as described (Migliaccio et al., 2002). The homogeneous population of pro-erythroblasts generated after 8-12 days in these cultures mature in 4 days up to the stage of orthochromatic erythroblasts once transferred in cultures supplemented with fresh medium and EPO (1 u/mL) alone (Calbiochem, Darmstadt, Germany). The effect of HDACi on the expression of the endogenous globin genes was determined by adding each of them at increasing concentrations at the beginning of the maturation culture. Cells were then harvested 4 days later for further analyses.

Phenotypic analysis. Cell morphology was analyzed according to standard criteria on cytocentrifuged (Shandon, Astmoor, England) smears stained with May-Grünwald-Giemsa (Sigma).

RNA isolation and quantitation of globin gene expression by real-time PCR. Total RNA was isolated from 10^6 cells using TRIZOL (INVITROGEN Life Technologies Inc. Carlsbad, CA, USA). Total RNA (1 μ g) was reverse transcribed with 250 ng random primers, 1 μ L dNTP (10 mM), 1 μ L RNase OUT (recombinant RNase inhibitor, 40 U/ μ L) (INVITROGEN Life Technologies), as described by the manufacturer. Quantitative real-time PCR was carried out in a

MOL #36772

7700 Sequence Detection System (PE Applied Biosystems, Norwalk, CT), using the TaqMan Master Mix containing AmpliTaq Gold DNA polymerase with 5'-3' nuclease activity, which hydrolyses a dual fluorescently labelled, target specific oligonucleotide (TaqMan probe). The sequence of the amplification primers and of the probes used for γ - and β -globin were described (Di Baldassarre et al., 2007). Primers and probes for α -globin were represented by: forward 5'-CTCTTCTGGTCCCCACAGACT-3'; reverse 5'-GGCCTTGACGTTGGTCTTG-3'; probe 5'-FAM-ACCATGGTGCTGTCTCCTGCCG-TAMRA-3' (from PE Applied Biosystem Warrington, Cheshire, Great Britain). Alpha hemoglobin stabilizing protein (AHSP) mRNA was evaluated with an assay on demand (TaqMan®Gene expression assays, PE Applied Biosystem). For multiplex PCR in Real-Time relative quantization, target and endogenous reference control were amplified in the same tube with the TaqMan hGAPDH, which contained the selected primer/probe set (20X solution, VIC label cat. 4310884E, Applied Biosystems, Foster City, CA, USA) according to the manufacture's instruction. Each determination was performed in triplicate. The level of a specific mRNA (X) was expressed in arbitrary units, using hGPDH as calibrator, according to the following algorithm: $\Delta Ct = [CtX - CtGPDH]$, where Ct is the X threshold cycle, and presented as $2^{-\Delta Ct} \cdot \gamma / (\gamma + \beta)$ and $\alpha / \text{non-}\alpha$ expression ratios were calculated as $2^{-\Delta Ct} \gamma / 2^{-\Delta Ct} \gamma + 2^{-\Delta Ct} \beta$ and $2^{-\Delta Ct} \alpha / 2^{-\Delta Ct} \gamma + 2^{-\Delta Ct} \beta$, respectively.

Determination of the cell HbF content. Cells were washed twice in HBSS and lysed in 50 mM Tris-HCl pH = 7.4, 150 mM NaCl, 1 mM EGTA, 1% Nonidet P-40, 0.25% sodium deoxicolate, 1 mM NaF, 0.5 mM Phenylmethanesulfonylfluoride, 1 μ g/mL Aprotinin, 1 μ g/mL Leupeptin, 1 mM sodium orthovanadate. Lysates were centrifuged for 10 min at 12000 g and supernatants used for HbF determination with a specific ELISA kit (BETHYL Lab Inc., Montgomery, TX, USA), using the HbF standard provided by the kit, as calibrator. The amount of the immuno-reaction was assessed by densitometry at 450 nm with a VICTOR³ Multilabel Counter 1420 (PerkinElmer Life & Analytical Sciences, Wallac Oy, Finland).

MOL #36772

Determination of H4 acetylation by flow cytometry. Levels of H4 acetylation were measured as described by Ronzoni et al., 2005. Briefly, 1×10^6 cells were fixed for 15 min in 1% formaldehyde in HBSS on ice and permeabilized with 200 μ L of 0.1% Triton X-100 in HBSS for 10 min at room temperature. Cells were first incubated with an anti-acetyl-Histone H4 (1:50 dilution; Upstate, Charlottesville, VA, USA) for 1 h at room temperature and then with the R-PE conjugated AffiniPure F(ab')₂ Fragment Donkey Anti-Rabbit IgG (H+L) (1:100 dilution; Jackson ImmunoResearch, Baltimore Pike, PA) for 1 h at room temperature in the dark. Cell fluorescence was analyzed with an Epics Elite ESP (Beckman Coulter, Miami, FL). Non-specific fluorescence signals were gated on cells incubated with R-PE conjugated AffiniPure F(ab')₂ Fragment Donkey Anti-Rabbit IgG (H+L) alone.

Human cell lines. The human non-erythroid U937 cell line and the human breast cancer ZR75.1 cell line were cultured in RPMI with 10% fetal calf serum, 100 U/ml penicillin, 100 μ g/ml streptomycin and 250 ng/ml amphotericin-B, 10 mM HEPES and 2 mM glutamine.

In vitro HDAC inhibition assay against human HDAC1 and HDAC4. The functional complexes containing human HDAC1 and HDAC4 were purified by immunoprecipitation (IP) from U937 and ZR75.1 cells, respectively. Cells were lysed in IP buffer (50 mM Tris-HCl pH = 7.0, 180 mM NaCl, 0.15% NP-40, 10% glycerol, 1.5 mM MgCl₂, 1 mM NaMoO₄, 0.5 mM NaF) with a protease inhibitor cocktail (Sigma), for 10 min on ice and centrifuged at 14700 g for 30 min. Extracts (1000 μ g/mL of protein) were pre-cleared by incubating with 20 μ L A/G plus Agarose (Santa Cruz, Santa Cruz, CA) for up to 1 h on a rocking table at 4 °C. Supernatants were, then, transferred into a new tube and incubated again either with an anti-HDAC1 (Abcam, Cambridge, MA) or anti-HDAC4 (Sigma) antibody (3 μ g) or with an irrelevant IgG (Santa Cruz), as negative control, overnight at 4 °C on a rocking table. The following day, 20 μ L A/G plus Agarose (Santa Cruz) was added to each IP and incubation continued for 2 h. The beads were washed twice in PBS and re-suspended in 20 μ L of sterile PBS. The HDAC assay was carried out using a labelled ³H-

MOL #36772

histone H4 peptide linked to streptavidine agarose beads, according to the supplier instructions (Upstate), as described by Mai et al., 2006.

Determination of H3, and α -tubulin acetylation. The effects of compound 9 and 24 on histone H3 and α -tubulin acetylation were determined by western blot analysis of protein extracts prepared from U937 cells that had been exposed to increasing compound concentrations for 16 h. For determination of α -tubulin acetylation, 25 μ g of total protein extracts were separated on a 10% polyacrylamide gel, blotted and probed by western blot with antibodies specific for acetylated α -tubulin (Sigma, dilution 1:500) and total Externally Regulated Kinases (ERKs, Santa Cruz, dilution 1:1000), as loading control. For quantification of histone H3 acetylation, 100 μ g of total protein extracts were separated on a 15% polyacrylamide gel, blotted and analyzed by western blot with antibodies specific either for the acetylated (Upstate, dilution 1:1000) or total form (Abcam, loading control) of histone H3.

Statistical Analysis. Statistical analysis was obtained with the Origin 5.0 software for Windows (Microcal Software Inc, Northampton, MA, USA).

Results

Screening of HDACi as inducer of reporter genes under the control of synthetic $\Delta\gamma$ - and β -globin promoters. Increasing concentrations [0.02-20 μ M] of the compounds described in Figure 1 were tested for their ability to affect the luciferase activity driven by either the $\Delta\gamma$ - or β -globin promoter expressed by GM979 cells incubated with each compound for at least 4 days. Since, under the conditions of the assay, GM979 cells have a doubling time of 48 h, this experimental design allowed the cells to proliferate at least twice in the presence of the HDACi, maximizing the likelihood that a compound would affect chromatin configuration. The results obtained are summarized in Table 1 as follows: a) maximal induction, or repression, on the activity of the $\Delta\gamma$ - and β -driven reporters; b) maximal alteration in $\Delta\gamma$ -F/($\Delta\gamma$ -F + 2 β -R)-reporter activity ratio and c) lower concentration of the compound which induced the maximal alteration. The number of cells present in the culture by the end of the assay was also recorded, and expressed as number of cell duplications, as a measure of toxicity. GM979 cells were incubated in parallel cultures with SAHA, and with the vehicle (DMSO), as positive and negative controls, respectively.

As in the studies summarized earlier (Cao et al., 2004 b), no relationship was observed between chemical structure of a compound and its effect on the activity of the $\Delta\gamma$ - and β -driven reporters. For example, among the three isomers 8, 9, and 10, two, 8 and 9, induced the $\Delta\gamma$ -driven reporter while the third, compound 10, did not. Among all of the HDACi tested, compounds 7, 8, 9, 11, 22, and 23 were all more effective than SAHA to induce expression of the $\Delta\gamma$ -driven reporter, with maximal activity between 0.2-2 μ M (Table 1). Some of them (7, 8, 11, 22 and 23) also induced the β -driven reporter activity. As a consequence, they had little, or no, effect on the $\Delta\gamma$ -F/($\Delta\gamma$ -F + 2 β -R) reporter activity ratio. Interestingly, compound 9 preferentially induced the activity of the $\Delta\gamma$ -driven reporter and increased the $\Delta\gamma$ -F/($\Delta\gamma$ -F + 2 β -R)-reporter activity ratio 2-fold more efficiently than SAHA (Table 1). Among all the HDACi investigated, compound 24 had the “unique” property to selectively increase the β -driven reporter activity.

MOL #36772

As sign of toxicity, the number of cells present by the end of the assay in the presence of the different compounds was measured and the number of cell duplications that had occurred during the assay calculated and presented in Table 1. Since this number is an exponent, 0 means that the number of cells remained constant (i.e. the number of those that died was equal to that of those that proliferated), a negative number means that the number of cells that died was higher than that of those that proliferated (toxicity), a positive number that the number of those that proliferated was higher than those that died. The interpretation that differences in positive numbers are indication of toxicity is debatable. In fact, it may be related to differences in cell cycle length due to increased time spent to reprogram the cell expression profile in response to the HDACi. With the exception of compound 11 and 23, none of the HDACi included in this study, including SAHA, decreased the number of GM979 cells alive by the end of the assay below input values (Table 1), an indication of their low toxicity in this cell system.

Activity of HDACi on the expression of the endogenous globin genes in primary erythroblasts obtained in vitro from normal donors.

Human erythroblasts obtained in human erythroblast massive amplification (HEMA) cultures express maximal and ontogenetically correct level of γ - and β -globin mRNA after 3-4 days of EPO-induced maturation (Di Baldassarre et al., 2007). Therefore, to evaluate the effects of HDACi on the expression of the endogenous globin genes, pro-erythroblasts were generated in vitro from normal donors and allowed to mature in the presence of selected compounds for 4 days. By the end of the 4 days, erythroblasts were harvested, counted (as indication of toxicity) and mRNA and protein extracted for quantitative RT-PCR and HbF determination, respectively. The compounds included in the assay were represented by 9 and 24, for their respective selectivity as γ - and β -promoter inducers in GM979 cells, and at least another member of each class (11 and 23, 25), with comparable IC_{50} in the HDAC inhibition screening, as control of specificity, and SAHA, for comparison. Compound 24 was included in the analyses because its selectivity as β -promoter

MOL #36772

inducer suggested to us that would represent a negative control. Each HDACi was used at the minimal concentration that was maximally effective (either 0.2 or 2 μ M) on GM979 cells.

As expected (Cao, 2004 a), SAHA (0.2-2 μ M) increased by 10-fold (from 0.05 up to 0.20-0.39) the $\gamma/(\gamma+\beta)$ ratio expressed by normal erythroblasts (Figure 2A). Among the tested compounds, 9 and 25 all significantly increased the $\gamma/(\gamma+\beta)$ expression ratio above background, with efficiency either comparable (9) or 30% lower (25) than SAHA. In contradiction with results obtained in GM979 cells, also compound 24 increased the $\gamma/(\gamma+\beta)$ ratios. Furthermore, this compound significantly, although modestly (by 50%), increased the amount of HbF contained in normal erythroblasts by the end of the culture (Figure 2B).

To detail the mechanism that mediated the increase in $\gamma/(\gamma+\beta)$ expression ratio in normal cells exposed to these compounds, a second set of experiments determined their concentration/response curve on the expression levels of γ - and β -globin mRNA. The effects of compound 11, 23 and 24 on γ - and β -globin expression remained modest up to concentrations of 3 μ M (results not shown). In contrast, both compound 9 and 24 transiently affected (induced or suppressed, respectively), expression of the endogenous β -globin at 0.02 μ M and significantly increased, by 2-fold, expression of γ -globin, with maximal effects at concentrations of 2 (9) and 0.2 (24) μ M, respectively. As a result, they also increased the $\gamma/(\gamma+\beta)$ expression ratio (Figure 3). However, the increase was clearly due to different mechanisms. In the case of the compound 9, the increase in expression ratio was due to the different magnitude of the increments of γ -globin and β -globin mRNA. In the case of compound 24, it was due to a combination of γ -globin mRNA increase and β -globin mRNA decrease. As a result, although the two compounds induced similar increases in the level of γ -globin mRNA (\approx from 2.0 to 3.5 $2^{-\Delta Ct}$), compound 24 was 3-times more active than 9 in increasing the $\gamma/(\gamma+\beta)$ ratio (from \approx 0.05 to 0.30 and 0.10, respectively) (Figure 3). Interestingly, compound 24 is the one that increased the HbF content per cell up to detectable levels (Figure 2B). Neither 9 or 24 consistently affected the levels of α -globin and AHSP, included in the analysis as control of specificity, expressed by normal erythroblasts (results not shown).

MOL #36772

Inhibition of human class I (HDAC1) and class IIa (HDAC4) HDACs and deacetylation of histone H3 and α -tubulin in U937 cells and of histone H4 in primary proerythroblasts.

HDACi library was based on the assumption that the maize HD2, although structurally different from mammalian HDACs, was considered a predictor model for mammalian class I HDACs (Brosch et al., 1996 a) while HD1-B (Lechner et al., 2000) and HD1-A (Brosch et al., 1996 b) were considered homologous to mammalian class I and II HDACs, respectively. More recent data are questioning the validity for human enzymes of class selectivity identified with the maize HDAC isoforms (Mai et al., 2006). Mammalian HDACs, in fact, are organized within the cells in complexes with other HDACs and DNA-binding proteins. In these complexes, one of the HDAC isoforms (usually of class I) exerts the catalytic function, while the other (usually of class IIa or b) acts as regulator of the catalytic enzyme (Minucci et al., 2006; Verdin et al., 2003). Therefore, to clarify the class selectivity of compound 9 and 24 for human HDACs, we performed inhibitory assays against the enzymatic activity of HDAC complexes purified by immunoprecipitation with antibodies specific for human HDAC1 (class I) and HDAC4 (class IIa) (Table 2). SAHA was used as control. Compound 24, that was a potent but not selective HDACi in maize, inhibited at least as efficiently as SAHA both class I and class IIa human HDACs ($IC_{50} = 0.2 \mu M$ in both cases). On the other hand, compound 9 was a weak (10-fold less efficient than SAHA) but class IIa selective HDACi. Therefore, in both cases, there was a good correlation between inhibition of maize and human HDAC class isoforms.

To clarify whether the HDAC inhibitory activity exerted by the compounds in vitro did correspond to increased histone acetylation in vivo, we measured the levels of acetylation of histone H3 and α -tubulin in U937 cells incubated with increasing concentration of compounds (Figure 4). Again, SAHA was included as control. The acetylation levels of α -tubulin were analyzed as indicator of functional inhibition of HDAC6, a class IIb HDAC isoform (Haggarty et al., 2003). In these experiments compound 9 and 24 induced similar levels of α -tubulin acetylation, levels that

MOL #36772

were slightly lower than those induced by SAHA. Therefore, compound 9 and 24, which had a clear different activity on class IIa HDAC (Table 2), exerted similar levels of inhibition on the class IIb isoform (Figure 4). Differential inhibition on class IIb and class IIa enzymes has been already reported for other molecules with HDACi activity (Mai et al., 2006) and is consistent with the distinctive chemical structure of the two classes of HDAC isoforms (Minucci et al., 2006). In addition, compound 9 was less efficient than SAHA and compound 24 was as efficient as SAHA in inducing histone H3 acetylation. The differences observed between compound 9 and 24 in histone H3 acetylation inducing activity *in vivo* are consistent with their potency as inhibitors of class IIa HDAC *in vitro* (see Table 2). It is also possible, however, that the difference between 9 and 24 in histone acetylation were due to the fact that the compounds had been used at equimolar rather than equitoxic concentrations.

As indication that the induction of HbF synthesis exerted by the compounds in primary erythroblasts was mediated by increased levels of histone acetylation, we compared by flow cytometry the acetylation state of histone H4 in normal erythroblasts that had matured in the absence or in the presence of compound 9 and 24 (Figure 5). The acetylation state of histone H3 was not analyzed because of low abundance of this protein in primary cells does not allow its evaluation by flow cytometry. A clear increase above background (AFU = 523 vs 170) in the acetylation state of histone H4 was observed in cells incubated with compound 9. A small, but detectable, increase in acetylation levels of histone H4 was also observed in cells incubated with compound 24 (256 vs 170).

The fact that HDACi had increased the levels of H4 acetylation in primary erythroblasts is a proof that they had inhibited HDAC activity in these cells. Two recent publications have demonstrated that increases in the levels of hystone H4 acetylation, obtained either through HDAC inhibition (Fathallah et al., 2007) or through activation of the p38 MAPK signalling (Aerbajinai et al., 2007), are responsible of the increased γ -globin expression induced in adult erythroblasts by butyrate and thalidomide, respectively. It is conceivable, therefore, that the increased levels of H4

MOL #36772

acetylation were directly responsible for the effects of compound 9 and 24 on γ -globin expression observed in this study.

Comparison of in vitro differentiation of normal and β^0 -thalassemic erythroblasts. It has been already reported that progenitor cells present in the blood from normal donors, as well as those present in the blood from β^0 -thalassemic patients, generate high numbers of erythroblasts in ex vivo expansion cultures (Migliaccio et al., 2002; Fibach et al., 1989). However, the differences between the in vitro maturation of normal and β^0 -thalassemic erythroblasts are still poorly defined. For this reason, a pilot study compared number, morphology and level of globin gene expression of erythroblasts obtained in vitro from normal and β^0 -thalassemic donors.

Under HEMA conditions, mononuclear blood cells from β^0 -thalassemic patients generated in 10-12 days a pro-erythroblast population that, although slightly lower in number (fold-increase, with respect to day 0 = 0.52 ± 0.22 vs 1.71 ± 0.84 in β^0 -thalassemic and normal cultures, respectively, $p < 0.01$), was equivalent in morphology to that generated by the corresponding normal cells (Figure 6). However, while normal pro-erythroblasts transferred in cultures containing only EPO matured in 4 days up to the stage of orthochromatic erythroblasts (Figure 6A), those obtained from β^0 -thalassemic patients matured poorly, remaining big in size, and with large nuclei and poorly condensed chromatin (Figure 6B). Such retarded maturation, was reflected by increased proliferation. In fact, normal pro-erythroblasts have limited proliferative capacity and proliferate only 1-3 times before initiating terminal maturation. Some of them will undergo apoptosis. As a result of the balance between the two processes, the number of cells after 4 days of maturation culture remain similar to input (fold increase = 0.85 ± 0.28). In contrast, in the corresponding maturation cultures seeded with β^0 -thalassemic pro-erythroblasts, the number of cells increased by ~2-fold (fold increase = 1.99 ± 0.93) by day 4. Although the difference between the two fold increase is not statistically significant, this result indicates that β^0 -thalassemic pro-erythroblasts proliferate more and/or dye less than normal cells when exposed to EPO alone.

MOL #36772

Differences were also observed in the levels of globin gene expressed by normal and β^0 -thalassemic erythroblasts after 4 days of maturation culture in EPO alone. AHSP was included in this analyses because of its abundant expression in erythroid cells (Kihm et al., 2002) and of the function of its product to bind free α -chains, stabilizing their structure and limiting their ability to participate in chemical reactions that generate reactive oxygen species (Feng et al., 2004). Normal orthochromatic erythroblasts expressed high levels of α - and β -globin ($2^{-\Delta Ct}$ in the 10-100 order of magnitude for both) and relatively low levels of γ -globin and AHSP ($2^{-\Delta Ct}$ in the 1-10 order of magnitude) (Figure 6). The levels of α - and β -globin expressed by normal cells obtained from different donors were very similar. In contrast, the donor variability in γ -globin and AHSP expression was as high as 10-fold (see the corresponding SD in Figure 6A). As expected, β^0 -thalassemic erythroblasts expressed levels of α - and γ -globin not statistically different from those expressed by the corresponding cells obtained from normal donors, but significantly less β -globin than normal cells ($2^{-\Delta Ct}$ in the order of magnitude of 1-10). Surprisingly, however, β^0 -thalassemic cells expressed significantly more (by 1-log) AHSP than normal cells (Figure 6). With the exception of AHSP, the subject-to-subject variability in globin genes expression in β^0 -thalassemic erythroblasts was much wider than that observed with the corresponding cells from normal donors (Figure 6B). More specifically, the difference in β -globin expression among erythroblasts obtained from different patients was so wide that in the case of two patients was only 10-fold lower than normal.

Compounds 9 and 24 restore the impaired in vitro maturation of β^0 -thalassemic erythroblasts.

In a last set of experiments, compounds 9 and 24 were tested for their ability to restore the impaired maturation expressed in vitro by erythroblasts obtained from β^0 -thalassemic patients. By morphological criteria, both compounds 9 and 24 restored the in vitro maturation of β^0 -thalassemic erythroblasts as orthochromatic cells became readily detectable in the cultures (Figure 7). By

MOL #36772

expression analysis, β^0 -thalassemic erythroblasts that matured in the presence of these compounds expressed significantly lower levels of β -globin (by 10-fold) and of AHSP (by 2-10-fold). In particular, the levels of AHSP expressed by β^0 -thalassemic cells exposed to compound 9 became no longer statistically different from those expressed by normal erythroblasts obtained from normal donors (Figure 6 and 7).

On average, neither compound 9 nor 24 affected the $\gamma/(\gamma+\beta)$ expression ratio in the β^0 -thalassemic erythroblasts (Figure 7 and results not shown). However, as shown by the detailed concentration/response curves on gene expression presented in Figure 8, in the case of two β^0 -thalassemic patients, those whose cells expressed the highest base line levels of β -globin, both compounds increased the $\gamma/(\gamma+\beta)$ ratio by 4-6 fold. Compound 9 did not significantly affect γ -globin expression but decreased that of β -globin (by 4-fold) in both patients. Compound 24 decreased β -globin expression (by 4-fold) and significantly increased γ -globin expression (by 2-fold) in both patients. In contrast with the results on normal cells, compound 9 decreased α -globin (by 4-fold) in one patient (Figure 8A). As a result, the $\alpha/\text{non-}\alpha$ expression ratio was not affected by the compound in one patient and was increased (by 20-fold) in the other one. Compound 24 had opposite effects on α -globin expression in the two patients: it increased it in one patient (the same who responded to compound 9) and decreased it in the other one (Figure 8B). As a consequence, the $\alpha/\text{non-}\alpha$ expression ratio was significantly increased (by 4-fold) in one patient and not affected in the other one.

Toxicity exerted by compounds 9 and 24 in cultures of normal and β^0 -thalassemic human erythroblasts. Last but not least, Figure 9 compares the toxicity exerted by compounds 9 and 24 in maturation cultures of normal and β^0 -thalassemic erythroblasts. In cultures of normal cells, both compound 9 and 24 decreased the number of cells alive by the end of the maturation culture less than SAHA, almost at all the concentrations tested. Therefore, both HDACi were at least no more toxic than SAHA at the concentrations (0.2 and 2 μM) found to be active as γ -globin

MOL #36772

inducer in normal erythroblasts. On the other hand, both compounds 9 and 24 were far less toxic in cultures of β^0 -thalassemic erythroblasts than they were in those of normal cells. Compound 24 had no effect on the cell number over the wide range of concentrations tested, while compound 9 exerted a 50% inhibitory activity at the concentration (3 μ M) that was effective as $\gamma/(\gamma+\beta)$ inducer in these cells.

Discussion

We have identified new synthetic HDACi capable to affect expression of γ -driven and/or of β -driven reporter activity in GM979 cells. Three compounds (8, 9, and 11) increased expression of both $^A\gamma$ - and β -driven reporter activities. The effects exerted on the two promoters were of different magnitude and occurred at different concentrations (Table 1). This allowed to defining a concentration window at which a compound was more potent as $^A\gamma$ - than as β -driven reporter inducer (Table 1). Compound 9, in particular, was 2-fold more potent than SAHA as inducer of $\gamma/(\gamma+\beta)$ expression ratio. On the other hand, compound 24, affected exclusively expression of the β -driven reporter in this synthetic model of Hb switch (Table 1).

Selected compounds were then tested for their ability to modify expression of the γ - and β -globin genes in normal erythroblasts. Two of them, compound 9 and 24, altered expression of the endogenous globin genes, with no, or minimal, effects, on that of α -globin and of AHSP (Figure 2, 3 and results not shown). Since maximal effects on γ - and β -globin expression were induced at different concentrations (Figure 3), also in this case, it was possible to identify a concentration window at which $\gamma/(\gamma+\beta)$ was significantly increased (3-8-fold). Interestingly, the concentrations (0.2-3 μ M) that mostly increased the $\gamma/(\gamma+\beta)$ ratio in primary and in GM979 cells were the same. The synthetic double-reporter assay did not always predict the activity of a compound on the endogenous promoters in primary cells. Two of the compounds (8 and 11) active on GM979 cells failed to induce the endogenous genes while one compound (9) induced the β -driven reporter while suppressing expression of the endogenous β -globin gene.

There was no apparent relationship between class selective inhibition of maize and human HDACs exerted by a compound (Supplemental Table 3 and Table 2) and its efficacy as $\gamma/(\gamma+\beta)$ inducer (Figure 2 and 3). In fact, compound 11, that was the most class-II selective HDACi (selectivity ratio: 176), was inactive in the γ -globin gene inducing assay, while the related but less class-II selective (selectivity ratio: 71) compound 9 was a good $\gamma/(\gamma+\beta)$ inducer (Figure 2 and 3). On

MOL #36772

the other hand, compound 24 lacked class selectivity and was more potent than compound 9 as $\gamma/(\gamma+\beta)$ inducer. Compound 9 and 24, however, exerted their effects through at least partially different mechanisms (preferential activation of γ - vs β -globin expression vs activation of γ - and inhibition of β -globin expression). The discovery that mammalian HDAC are assembled within the cells as multicomplexes of more than one isoenzyme, each one exerting a specific function, with many other DNA-binding proteins (Minucci et al., 2006) is rendering obsolete both the concept of class selectivity and the use of the maize enzyme assay as a screening method to predict pharmacologically relevant HDACi. Furthermore, it is likely that the globin gene locus is regulated by a specific HDAC complex. In this regard, it has been recently reported that the effect of butyrate on γ -globin expression is mediated by the class I HDAC3 (Mankidy et al., 2006), an enzyme part of the complex that include HDAC4 (Verdin et al., 2003). It is conceivable, then, that the identification of the specific HDAC complexes involved in the regulation of the globin locus, that may include but not be limited to the HDAC3-HDAC4 complex, will finally allow the prediction of the chemical structure of the HDACi most effective as HbF inducer.

Orthochromatic erythroblasts obtained from normal donors expressed high levels of AHSP and of globin genes (Figure 6). Surprisingly, the levels of AHSP expressed by erythroblasts obtained from different donors were different by 1-log (Figure 6). Three-fold variability in AHSP expression has been recently described in reticulocytes obtained from different normal subjects. This variability has been ascribed to a T-homopolymer polymorphism in the putative gene promoter (T18 vs T15) (Lai et al., 2006). The higher (10-fold) variability observed here might be due either to the fact that the T18 polymorphism affects most prominently AHSP expression at early than at late stages of maturation, or to the existence, in the AHSP locus, of additional regulatory polymorphisms, still to be identified. Further studies will clarify this point.

Erythroblasts obtained from β^0 -thalassemic patients had a clearly abnormal maturation profile in response to EPO. β^0 -Thalassemic erythroblasts matured poorly, as documented by their

MOL #36772

morphology, and expressed levels of β -globin 1-5-log lower than normal (Figure 7). Surprisingly, β^0 -thalassemic erythroblasts expressed levels of AHSP 10-times higher than normal. The reason of such high expression is unknown. Since expression of AHSP increases with erythroblast maturation (Dos Santos et al., 2004), it is unlikely that such high levels are a reflection of retarded cell maturation. In stead, the significant ($p < 0.05$) linear correlation between the amount of AHSP and that of α -globin mRNA present in erythroblasts obtained from different patients (not shown), suggests that it might result from an auto-regulatory loop, triggered by the concentration of uncoupled α -chains in the cytoplasm of these cells.

Both compounds 9 and 24 restored the morphological maturation of β^0 -thalassemic erythroblasts (Figure 7). The molecular mechanism used by each compound is not obvious. In fact, only in the case of two patients, out of five analyzed, it was possible to demonstrate that the improved maturation was associated with increased $\gamma/(\gamma+\beta)$ ratios (Figure 8 and Supplemental Figure 1). The alterations induced in these two patients were consistent with those induced in normal cells: compound 9 decreased β -globin expression while compound 24 increased γ -globin expression and reduced β -globin expression. It is possible that similar modifications were induced by these compounds in erythroblasts from all the patients included in this study but went undetected because of the time point (4 days of culture) chosen for analysis. Heterogeneity of in vivo response of β^0 -thalassemic and sickle cell anemia patients to treatment with the HDACi butyrate has already been described (Perrine et al., 1993; Sher et al., 1995). Recently, it has been reported that such heterogeneity is retained by cells obtained from the same patients in vitro (Fathallah et al., 2007). Therefore, a comparison of the response to compound 9 and 24 of erythroblasts obtained in vitro from butyrate-responsive and non-responsive patient might provide indications whether these compounds could be used for personalized therapies. These experiments will be performed in the near future.

MOL #36772

A difference between the response to compound 9 and 24 of normal and β^0 -thalassemic erythroblasts was represented by the fact that in normal cells, compound 9 and 24 did not affect α -globin and AHSP expression while both of them reduced the expression of these genes in β^0 -thalassemic erythroblasts: the reduction of α -globin expression was modest (by 5-fold) and donor-dependent; the reduction of AHSP expression was of greater magnitude (in the case of compound 9, it was reduced down to the levels observed in normal cells) and donor-independent (Figure 7, 8 and Supplemental Figure 1). It is tempting to interpret this last result as an indication that the level of AHSP expression was normalized because the concentration of free α -chains in the cytoplasm of the cells had been reduced. However, it is also possible that the effects of HDACi on AHSP expression might be independent from their action on the β -globin locus. As an example, in β^0 -thalassemic erythroblasts, HDACi might interfere with the homeostatic regulatory loop, involving α -globin and AHSP, activated by the cells to compensate for the presence of defective β -chains. In other words, the effects of HDACi on AHSP regulation might function as modifier of the β -thalassemic trait, at least in vitro. The hypothesis that AHSP might represent a gene modifier that, as the HPFH mutation, might ameliorate the phenotype of thalassemic patients was originally suggested by the observation that double AHSP^{null} β -thalassemic mice have an exacerbated phenotype (Kong et al., 2004). Although not supported by clinical evidence so far (Viprakasit et al., 2004; Lai et al., 2006), this hypothesis is worthy of further investigation as might lead to identify additional targets for the therapy of sickle cell anemia and/or β -thalassemia.

In conclusion, we have identified two new HDACi, 9 and 24, that specifically altered the levels of γ - and β -globin expressed by normal erythroblasts increasing the $\gamma/(\gamma+\beta)$ ratio in these cells with limited donor to donor variability. One of the compounds (24) also increased the HbF content of normal cells. Both compounds restored the defective morphological maturation and increased the $\gamma/(\gamma+\beta)$ ratio expressed by β^0 -thalassemic erythroblasts in vitro. Because of their low

MOL #36772

toxicity in all of the assays investigated, we suggest that compounds 9 and 24 might represent new candidates for pharmacological reactivation of HbF for the treatment of β^0 -thalassemic patients.

MOL #36772

Acknowledgements

Recombinant human SCF was provided by Amgen (Thousand Oaks, CA, USA, MTA No. 19982634-005). George Stamatoyannopoulos, Mitchell Weiss and George Atweh are gratefully acknowledged for support and encouragement. The collaboration of Fabrizio Martelli for graphic assistance, of Mariacristina Di Rico for the initial luciferase assays and of Valerie Smith for editorial assistance is also greatly appreciated.

References

- Aerbajinai W, Zhu J, Gao Z, Chin K, Rodgers GP (2007) Thalidomide induces γ -globin gene expression thorough increased reactive oxygen species-mediated p38 MAPK signalling and histone H4 acetylation in adult erythropoiesis. *Blood*, prepublished online July 9.
- Atweh GF, Sutton M, and Nassif I (1999) Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. *Blood* **93**:1790-1797.
- Atweh GF, and Schechter AN (2001) Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. *Curr Opin Hematol* **8**:123-130.
- Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, and De Montalembert M (2003) Hydroxyurea can eliminate transfusion requirements in children with severe β -thalassemia. *Blood* **102**:1529-1530.
- Brosch G, Lusser A, Goralik-Schramel M, and Loidl P (1996, a) Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. *Biochemistry* **35**:15907-15914.
- Brosch G, Goralik-Schramel M, and Loidl P (1996, b) Purification of histone deacetylase HD1-A of germinating maize embryos. *FEBS Lett* **393**:287-291.
- Cao H (2004, a) Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. *Hematology* **9**:223-233.
- Cao H, Stamatoyannopoulos G, and Jung M (2004, b) Induction of human γ globin gene expression by histone deacetylase inhibitors. *Blood* **103**:701-709.
- Constantoulakis P, Knitter G, and Stamatoyannopoulos G (1989) On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. *Blood* **74**:1963-1971.
- Di Baldassarre A, Di Rico M, Di Noia A, Confini T, Iacone A, Marchisio M, Miscia S, Alfani E, Migliaccio AR, Stamatoyannopoulos G, and Migliaccio G (2007) Protein kinase Calpha is

MOL #36772

differentially activated during neonatal and adult erythropoiesis and favors of a reporter gene under the control of the γ globin-promoter in cellular models of hemoglobin switching. *J Cell Biochem* In press.

Dos Santos CO, Duarte AS, Saad ST, and Costa FF (2004) Expression of alpha-hemoglobin stabilizing protein gene during human erythropoiesis. *Exp Hematol* **32**:157-162.

Fathallah H, Weinberg RS, Galperin Y, Sutton M, Atweh GF (2007) Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. *Blood*, prepublished online July 17.

Felsenfeld G, and Groundine M (2003) Controlling the double helix. *Nature* **421**:448-453.

Feng L, Gell DA, Zhou S, Gu L, Kong Y, Li J, Hu M, Yan N, Lee C, Rich AM, Armstrong RS, Lay PA, Gow AJ, Weiss MJ, Mackay JP, and Shi Y (2004) Molecular mechanism of AHSP-mediated stabilization of alpha-hemoglobin. *Cell* **119**:629-640.

Fibach E, Manor D, Oppenheim A, and Rachmilewitz EA (1989) Proliferation and maturation of human erythroid progenitors in liquid culture. *Blood* **73**:100-103.

Forsberg EC, Downs KM, Christensen HM, Im H, Nuzzi PA, and Bresnick EH (2000). Developmentally dynamic histone acetylation pattern of a tissue specific chromatin domain. *Proc Natl Acad Sci U. S. A.* **97**:14494-14499.

Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc Natl Acad Sci USA* **100**:4389-4394.

Hassig CA, and Schreiber SL (1997) Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. *Curr Opin Chem Biol* **1**:300-308.

Kihm AJ, Kong Y, Hong W, Russell JE, Rouda S, Adachi K, Simon MC, Bobel GA, and Weiss MJ (2002) An abundant erythroid protein that stabilizes free alpha-hemoglobin. *Nature* **417**:758-763.

Kölle D, Brosch G, Lechner T, Lusser A, and Loidl P (1998) Biochemical methods for analysis of histone deacetylases. *Methods* **15**:323-331.

MOL #36772

- Kong Y, Zhou S, Kihm AJ, Katein AM, Yu X, Gell DA, Mackay JP, Adachi K, Foster-Brown L, Loudon CS, Gow AJ, and Weiss MJ (2004) Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. *J Clin Invest* **114**:1457-1466.
- Lai MI, Jiang J, Silver N, Best S, Menzel S, Mijovic A, Colella S, Ragoussis J, Garner C, Weiss MJ, and Thein SL (2006) Alpha-hemoglobin stabilizing protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia. *Br J Haematol* **133**:675-682.
- Lechner T, Lusser A, Pipal A, Brosch G, Loidl A, Goralik-Schramel M, Sendra R, Wegener S, Walton JD, and Loidl P (2000) RPD3-Type histone deacetylases in maize embryos. *Biochemistry* **39**:1683-1692.
- Letvin NL, Linch DC, Beardsley GP, Mc Intyre KW, and Nathan DG (1984). Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. *N Engl J Med* **310**:869-873.
- Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, and Brosch G (2006) Design, Synthesis, and Biological Properties of Novel Uracil-Containing Histone Deacetylase Inhibitors. *J Med Chem* **49**:6046-6056.
- Mankidy R, Faller DV, Mabaera R, Lowrey CH, Boosalis MS, White GL, Castaneda SA, Perrine SP (2006) Short-chain fatty acids induce γ -globin gene expression by displacement of a HDAC3-NCoR repressor complex. *Blood* **108**:3179-3186.
- Migliaccio G, Di Pietro R, Di Giacomo V, Di Baldassarre A, Migliaccio AR, Maccioni L, Galanello R, and Papayannopoulou T (2002) In vitro mass cell production of human erythroid cells from the blood of normal donors and β^0 -thalassemic patients. *Blood Cells Mol Dis* **28**:169-180.
- Migliaccio G, Di Baldassarre A, Di Rico C, Di Noia A, Nakamoto B, Cao H, Skarpidi E, and Migliaccio AR (2005) Spontaneous switch from γ - to β -globin promoter activity in a stable transfected dual reporter vector. *Blood Cells Mol Dis* **34**:174-180.
- Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nat Rev Cancer* **6**:38-51.

MOL #36772

- Noguchi CT, Rodgers GP, Serjeant G, and Schechter AN (1988) Levels of fetal haemoglobin necessary for the treatment of sickle cell disease. *N Engl J Med* **318**:96-99.
- Olivieri NF (1999) The beta-thalassemias. *N Engl J Med* **341**:99-109.
- Papayannopoulou T, Torrealba de Ron A, Veith R, Knitter G, and Stamatoyannopoulos G (1984) Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. *Science* **224**:617-619.
- Perrine SP, Rudolph A, and Faller DV (1988) Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. *Proc Natl Acad Sci USA*. **85**:8540-8542.
- Perrine SP, Miller BA, and Faller DV (1989) Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and β -thalassemia. *Blood* **74**:454-459.
- Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, and Olivieri NF (1993) A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β -globin disorders. *N Engl J Med* **328**:81-86.
- Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, and Nathan DG (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. *J Clin Invest* **74**:652-656.
- Ronzoni S, Faretta M, Ballarini M, Pelicci PG, and Minucci S (2005). New methods to detect histone acetylation levels by flow cytometry. *Cytometry Part A* **66A**:52-61.
- Sher GD, Ginder GD, Little J, Yang S, Dover GJ, and Olivieri NF (1995) Extended therapy with intravenous arginine butyrate in patients with β -hemoglobinopathies. *N Engl J Med* **332**:1606-1610.
- Skarpidi E, Vassilopoulos G, Li Q, and Stamatoyannopoulos G (2000) Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin. *Blood* **96**:321-326.
- Stamatoyannopoulos G, and Grosveld F (2001) Hemoglobin switching, in *The Molecular Basis of Blood Diseases*, 3rd ed. (Stamatoyannopoulos, G., Majerus, P. W., Perlmutter, R. M., Varmus, H., Eds.) pp 135-182, W.B. Saunders Publishing Co., Philadelphia.

MOL #36772

Trecartin RF, Liebhaber SA, Chang JC, Lee YW, and Kan YW (1981) β^0 -thalassemia in Sardinia is caused by a nonsense mutation. *J Clin Invest* **68**:1012-1017.

Veith R, Galanello R, Papayannopoulou T, and Stamatoyannopoulos G (1985) Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. *N Engl J Med* **313**:1571-1575.

Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. *Trends Genet* **19**:286-293.

Viprakasit V, Tanphaichitr VS, Chinchang W, Sangkla P, Weiss MJ, and Higgs DR (2004) Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia. *Blood* **103**:3296-3299.

Zhang J, Sun X, Qian Y, and Maquat LE (1998) Intron function in the nonsense-mediated decay of beta-globin mRNA: indications that pre-mRNA splicing in the nucleus can influence mRNA translation in the cytoplasm. *RNA* **4**:801-815.

Footnotes

This work was partially supported by grants from AIRC 2006 (A.M.), PRIN 2006038137_005 (A.M.), PRIN 2006052835_003 (L.A.); Ministero per l'Università e la Ricerca Scientifica e Tecnologica, grant no. RBNE0189JJ 006, RBNE01sp72 003 (A.R.M.) and MM06103241 (G.M.); institutional funds from the University of Illinois at Chicago, IL; and a Grant from the National Cancer Institute, USA P01-CA108671-01A2 to the MPD-RC; the European Union (LSHC-CT2005-518417) (L. A.). This work was partially presented as poster at the annual meeting of the American Society of Hematology in 2004 [Mai A, Massa S, Di Noia A, Jelacic K, Alfani E, Di Rico MC, Di Baldassarre A, Migliaccio AR and Migliaccio G (2004) Aroyl-Pyrrolyl-Hydroxy-Amides (APHAs), a Novel Family of Synthetic Histone Deacetylase Inhibitors, Are Potent Inducers of Human γ -Globin Gene Expression. *Blood*. 104:1216.] and as oral presentation at the annual meeting of the European Haematology Association in 2005 [Di Noia A, Jelacic K, Mai A, Massa S, Di Rico MC, Di Baldassarre A, Alfani E, Migliaccio AR and Migliaccio G (2005) Identification of a New Family of Synthetic Histone Deacetylase (HDAC) Inhibitors that Strongly Reactivate $[\gamma]$ -Globin Gene Expression by a Novel Screening Strategy Involving Primary Human Erythroblasts].

Legends for Figures

Figure 1. Chemical structures of the HDACi included in the library analyzed in this study.

The library contains previously reported and newly synthesized HDACi identified using the maize HDACs inhibitory assay (see supplemental data). These compounds belong to three different chemical classes: aroyl pyrrolyl hydroxyamides or APHAs (1-6), aryloxopropenylpyrrolyl hydroxyamides (7-19), and uracil-based hydroxyamides or UBHAs (20-25). The rectangles highlight the two compounds (9 and 24) most extensively analyzed in this study. The chemical structure of SAHA (vorinostat) is included for comparison.

Figure 2. Effects of selected HDACi on the $\gamma/(\gamma+\beta)$ mRNA ratio (A) and on the HbF content (B) expressed by primary erythroblasts obtained from normal donors.

Pro-erythroblasts were obtained in HEMA and were induced to mature for 4 days with EPO in the presence or in the absence of the indicated HDACi. HDACi were used at the minimal concentration that was effective on GM979 cells and presented in Table 1. These concentrations are either 0.2 (9 and 25) or 2 (11, 23,24) μ M. Results obtained in parallel cultures incubated with SAHA (0.2-2 μ M) are presented for comparison. Data are presented as mean(\pm SD) of 5-6 separate assays, each with a different donor, performed in triplicate. The $\gamma/(\gamma+\beta)$ mRNA ratios observed in cultures with or without DMSO are 0.03 ± 0.005 and 0.023 ± 0.004 , respectively. Values statistically different from untreated controls are indicated by * ($p < 0.5$) and ** ($p < 0.01$).

Figure 3. Concentration/response curve for compounds 9 (A) and 24 (B) on the levels of β - and γ -globin mRNA, and on the $\gamma/(\gamma+\beta)$ ratio, expressed by normal human erythroblasts.

Cells incubated with DMSO were used as negative control (Contr). Results are presented as mean (\pm SD) of a single experiment performed in triplicate and are representative of those observed in at least 5-6 experiments, each with a different donor. § and * indicate values statistically different ($p < 0.05$) from controls by paired t-test and ANOVA, respectively. See legend to Figure 2 for

MOL #36772

further details. In the experiment presented in panel B, untreated cells expressed levels of β and γ globin mRNA of 23.3 ± 1.8 vs 2.2 ± 0.1 , respectively. The values expressed by untreated cells in the experiment presented in panel A were not measured.

Figure 4. Effects of compound 9 and 24 on the levels of H3 and α -tubulin acetylation in U937 cells. U937 cells were incubated either with increasing concentration of SAHA (positive control) and of compound 9 and 24 (0.2-20 μ M in all the cases), as indicated. Untreated cells (C) and cells incubated with DMSO alone (D) were analyzed as negative controls.

Figure 5. Effects of compounds 9 and 24 on the level of histone H4 acetylation in primary erythroblasts obtained from normal donors. Pro-erythroblasts obtained in HEMA were cultured with EPO alone (Control, top panel) or with EPO plus DMSO (vehicle, negative control), or compound 9 or 24, as indicated. After 4 days, the cells were harvested and the levels of H4 acetylation measured by flow cytometry. The forward and side scatter plots present the gate used for the fluorescence analyses presented in the histograms on the right. The white and grey area correspond to the fluorescence intensity expressed by cells labelled with an irrelevant antibody or with the anti-acetyl-histone H4, respectively. The average fluorescence intensity (AFU, in arbitrary units) expressed by cells incubated with the anti-acetyl-histone H4 is reported on the right, and is proportional to the acetylation state of histone H4 in the cell population analyzed (Ronzoni et al., 2005).

Figure 6. Comparison of the in vitro maturation of primary pro-erythroblasts obtained from normal donors (A) or from β^0 -thalassemic patients (B), as indicated. Pro-erythroblasts were obtained in the proliferative phase of HEMA (prol) and induced to mature for 4 days with EPO. Cell morphology before (Prol) and after maturation was analyzed by May-Grunwald staining (original magnification 40X). Expression levels of α -, β - and γ -globin, and AHSP, in cells at the end of the maturation culture were analyzed by quantitative RT-PCR and expressed as $2^{-\Delta Ct}$. Data obtained with a total of 3-7 normal donors and 5 thalassemic patients (each donor a different symbol) are presented. The straight line and the shaded area indicate the mean (\pm SD) obtained in all

MOL #36772

the experiments. Expression levels in β^0 -thalassemic erythroblasts statistically different ($p < 0.01$) from those of normal cells are indicated by *.

Figure 7. Both compounds 9 (top panels) and 24 (bottom panels) restore the impaired in vitro maturation of pro-erythroblasts from β^0 -thalassemic patients. The morphology of the cells before (Prol) and after the 4 days of maturation in the presence of EPO plus each compound was analyzed by May-Grunwald staining (original magnification 40X). Expression levels of α -, β - and γ -globin, and AHSP, in cells cultured for 4 days in the presence of the compounds were analyzed by quantitative RT-PCR and expressed as $2^{-\Delta Ct}$. Data obtained with a total of 5 β^0 -thalassemic patients (each donor a different symbol, the same as in Figure 6B) are presented. The levels of mRNA expressed by cells treated with DMSO alone are presented as control and ranged from 91 (γ -globin) to 107 (α -globin) percent of those expressed by untreated cells and presented in Figure 6. The straight line and the shaded area indicate the mean (\pm SD) obtained in all the experiments. Values statistically different from those expressed by untreated normal and β^0 -thalassemic erythroblasts, and presented in Figure 6, are indicated by * and by **, respectively.

Figure 8. Concentration/response curves of compounds 9 (A) and 24 (B) on the levels of α -, β - and γ -globin, as well as of AHSP, mRNA expressed by primary erythroblasts obtained from two separate β^0 -thalassemic patients (each color, a different donor). The corresponding α /non- α and γ / γ + β ratios are reported on the bottom (see legend to Figure 7 for more information). Results are presented as mean (\pm SD) of single experiments performed in triplicate. * indicate values statistically different ($p < 0.05$) from controls.

Figure 9. Toxicity exerted by compounds 9 (square) and 24 (circle) in cultures of normal (top panel) and β^0 -thalassemic (bottom panel) erythroblasts, as indicated. Toxicity was evaluated on the basis of the number of cells observed by the end (4 days) of the maturation culture. The number of cells observed in the presence of SAHA (triangle) and of DMSO (the vehicle, shaded area) is also reported, for comparison. Results are expressed as percent of untreated controls ($100\% = 0.85 \pm 0.28$ vs $1.99 \pm 0.93 \times 10^6$ cells in cultures from normal and β^0 -thalassemic donors,

MOL #36772

respectively) and are presented as mean (\pm SD) of 5-6 separate assays. The arrows indicate the concentrations used in Figure 2 and 7, respectively.

MOL #36772

TABLE 1

Reporter-Inducer Activity of Compounds **1-25** on GM979 Cells^a

Compd.	Conc. (μ M)	γ -F (as % of control)	β -R (as % of control)	$\gamma/(\gamma+2\beta)$ (as % of control)	Number of Cell Duplications ^b
1	2	423.3	210.2	198.7	0.64 \pm 0.17
2	0.6	499.5	279.6	177.1	0.69 \pm 0.17
3	2	514.4	529	99	0.19 \pm 0.17
4	6	25.6	134.6	19.4	2.36 \pm 0.17
5	20	167.6	242.3	68.5	2.34 \pm 0.17
6	6	179.5	178	100.3	0.96 \pm 0.17
7	2	937.7	544.4	173.8	0.34 \pm 0.17
8	2	266.5	350.8	77.5	2.42 \pm 0.17
9	2	897.9	338.5	264.8	1.07 \pm 0.17
10	0.2	78.6	94.8	83.7	1.9
11	2	255.7	207.6	122.9	-0.11 \pm 0.17
12	Toxic	ND ^c	ND	ND	ND
13	0.02	95.5	83.0	114.0	2.0
14	0.2	100.2	98.5	102.4	2.2
15	0.2	125.0	113.3	112.0	2.1
16	0.2	167.7	115.6	142.8	2.0
17	0.2	107.2	120.1	90.0	1.0
18	0.2	114.8	112.0	102.0	1.4
19	0.2	99.5	98.1	100.0	1.2
20	2	85.8	131.8	65.3	1.79
21	0.2	181.3	178.9	101.3	0.20
22	2	261.8	272.5	96.1	0.29
23	2	268.6	253.7	101.3	-0.70
24	2	117.7	234.8	50.3	0
25	0.2	173.0	267.8	64.7	1.94
SAHA	0.2	189.1	153.1	123.2	1.29
DMSO	1% v/v	100	100	100	2.4 \pm 0.17

^aStandard deviations are within 10% and are not reported for clarity. ^bThe number of cell duplications was calculated according to the formula: number of duplications at day x = log₂ (cell number at day x/cell number at day 0). ^cND, not determined.

MOL #36772

TABLE 2

Comparison of the inhibitory activity of compounds 9, 24 and SAHA on human class I (HDAC1) and II (HDAC4) HDAC isoforms purified from human cell lines. Enzymatic activities are expressed as % of the control activity exerted by the enzyme alone.

Compound	Class I (HDAC1) (%)	Class IIa (HDAC4) (%)
SAHA		
0.2 μ M	52.2 \pm 1.4	66.6 \pm 1.6
2.0 μ M	15.5 \pm 1.4	33.8 \pm 1.1
9		
0.2 μ M	108.2 \pm 7.1	94.3 \pm 0.6
0.6 μ M	116.0 \pm 2.8	98.1 \pm 0.3
2.0 μ M	113.3 \pm 4.3	89.8 \pm 0.7
6.0 μ M	107.5 \pm 3.9	78.0 \pm 0.2
20 μ M	102.8 \pm 2.1	41.8 \pm 0.8
24		
0.2 μ M	55.1 \pm 0.7	70.3 \pm 0.7
0.6 μ M	29.8 \pm 1.6	43.5 \pm 0.01
2.0 μ M	14.2 \pm 0.9	30.8 \pm 0.6
6.0 μ M	9.8 \pm 0.07	18.4 \pm 0.8
20 μ M	8.5 \pm 0.05	17.0 \pm 0.6




Figure 1





Figure 2

Compound 9

A



Compound 24

B




Figure 3




Figure 4






Figure 5

A**Normal Subjects****Prol** **4 Days of maturation with EPO****B****Thalassemic Patients****Prol** **4 Days of maturation with EPO****Figure 6**

Thalassemic Patients

Prol 4 Days of maturation with EPO






Figure 7

Compound 9

A




Figure 8A

Compound 24

B





Figure 8B

Normal Donors



Thalassemic Patients




Figure 9